Core Viewpoint - NeuroThera Labs Inc. has advanced its collaboration with Clearmind Medicine Inc. by publishing an international patent application for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2]. Company Overview - NeuroThera Labs Inc. is a clinical-stage biotech company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [4]. - Clearmind Medicine Inc. is a clinical-stage neuroplastogens pharmaceutical biotech company dedicated to discovering and developing psychedelic-derived therapeutics for widespread health issues, including alcohol use disorder [5]. Market Potential - The combination therapy of 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) is positioned to address obesity, which affects over 890 million adults globally, and MASLD, impacting approximately 30% of the global adult population [2]. - The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease and the need for innovative alternatives to GLP-1 agonists [3]. Therapeutic Advantages - The MEAI-PEA combination may provide a safer, non-hallucinogenic neuroplastogen treatment option that is potentially more cost-effective than existing GLP-1 agonists for obesity and MASLD [2][3]. - The collaboration aims to meet the growing demand for effective, tolerable, and safe treatments in the obesity and liver health sectors [3].

Core Viewpoint - The collaboration aims to evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 as a potential treatment for glioblastoma, the most common and aggressive form of brain cancer [1] Group 1: Study Details - The novel combination therapy will be studied as part of the Phase II adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute [1] - This study builds on previously reported positive Phase II results involving INO-5401 in glioblastoma [1] Group 2: Treatment Mechanism - The combination adds a novel, first-in-class PD-1/CTLA-4 bi-specific immunotherapy, which potentially provides additional checkpoint inhibition through CTLA-4 binding [1]